Signal Intensity Ratio of Cochlear Basal Turn Increased in Affected Ear in Meniere Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 2, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Jan. 2, 2024 -- The affected ear in Meniere disease has significantly increased the signal intensity ratio (SIR) of the cochlear basal turn, indicating potential damage of the blood-labyrinth barrier, according to a study published online Dec. 6 in the European Archives of Oto-Rhino-Laryngology.

Weidong Zhang, M.D., from the Zhengzhou University People's Hospital and Henan Provincial People's Hospital in China, and colleagues enrolled 30 patients with unilateral definite Meniere disease and 24 healthy controls to compare the SIR of the cochlear basal turn. The differences of bilateral SIR were compared between Meniere disease and healthy controls, and the correlation was examined between the SIR of the affected ear and the grades of cochlear and vestibular hydrops in Meniere disease.

The researchers observed a significant increase in the SIR of the affected ear in Meniere disease versus the unaffected ear. Healthy controls had no significant difference in SIR between the two ears. The SIR was higher in the unaffected ear in Meniere disease than that of both ears in healthy controls. There was a positive correlation observed for SIR in the affected ear in Meniere disease with hydrops in both the cochlea and vestibula.

"As increased permeability of the blood-labyrinth barrier precedes the formation of endolymphatic hydrops, it is suggested that disruption of the blood-labyrinth barrier may contribute to the development of Meniere disease in patients," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-03 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords